Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension - Lipton, R B; Tepper, S J; Silberstein, S D (Cephalalgia, 2021)